Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals | COVID-19 Impact Analysis

Global PD-1/PD-L1 Inhibitors Market $65.7 Billion by 2027

The global market for PD-1/PD-L1 inhibitors anticipated to attain $65.7 billion by 2027, expanding at a double-digit CAGR of 13.2% over the forecast period, driven by universal mechanism of action, rapid expansion of products across multiple indications, and rich pipeline of potential candidates.

  • Other factors driving the market growth include increasing demand for PD-1/PD-L1 inhibitors, combined use of all approved checkpoint inhibitors, emerging innovation landscape.
Global PD-1/PD-L1 Inhibitors Market

The PD-1/PD-L1 checkpoint inhibitors were among the first cancer immunotherapies to be approved and they have transformed the oncology treatment landscape, offering hope to patients as new options for hard-to-treat tumors. Their universal mechanism of action enabled the rapid expansion of products across multiple indications and created blockbusters in the process, most notably Keytruda and Opdivo.

  • Multi-indicationality, along with the commercial potential has attracted numerous players, rapid indication expansion such as such as non-small cell lung cancer (NSCLC), malignant melanoma (MM), kidney cancer (renal cell carcinoma), small cell lung cancer (SCLC), urogenital cancer (bladder and prostate cancer), head and neck cancer (head and neck squamous cell carcinoma), and other cancers, and the strategic sequencing of indications.

Till-date, seven global PD-1/PD-L1 inhibitors are on the market with approvals across 17 cancer indications, many of which are served by multiple agents: Keytruda, Opdivo, Tecentriq, Imfinzi, Bavencio, Libtayo, and Jemperli.

  • Pembrolizumab (Keytruda) was developed by Merck and first approved by the US FDA in 2014 for the treatment of melanoma. It was later approved for metastatic non-small cell lung cancer and head and neck squamous cell carcinoma.
  • Nivolumab (Opdivo) was developed by Bristol-Myers Squibb and first approved by the FDA in 2014 for the treatment of melanoma. It was later approved for squamous cell lung cancer, renal cell carcinoma, and Hodgkin’s lymphoma.
  • Cemiplimab (Libtayo) was developed by Regeneron Pharmaceuticals and first approved by the FDA in 2018 for the treatment of cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation.
  • Dostarlimab (Jemperli) was developed by GlaxoSmithKline and was first approved for the treatment of mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer by the FDA in 2021. Later, it was granted accelerated approval for the treatment of mismatch repair deficient (dMMR) recurrent or advanced solid tumors.
  • Atezolizumab (Tecentriq) is a fully humanized IgG1 (immunoglobulin 1) antibody developed by Roche (Genentech). In 2016, the FDA approved atezolizumab for urothelial carcinoma and non-small cell lung cancer.
  • Avelumab (Bavencio) is a fully human IgG1 antibody developed by Merck Serono and Pfizer. Avelumab is FDA approved for the treatment of metastatic Merkel-cell carcinoma.
  • Durvalumab (Imfinzi) is a fully human IgG1 antibody developed by AstraZeneca. Durvalumab is FDA approved for the treatment of urothelial carcinoma and unresectable non-small cell lung cancer after chemoradiation.

The global market for PD-1 and PD-L1 inhibitors research report provides market size ($million 2017 to 2027), market share analysis, growth trends and forecast (CAGR%, 2021 to 2027).

The global market for PD-1/PD-L1 inhibitorssegmented by product (drug class/brand) – PD-1 inhibitors [Keytruda (pembrolizumab), Opdivo (nivolumab), Libtayo (cemiplimab), Jemperli (dostarlimab)], PD-L1 inhibitors [Tecentriq (atezolizumab), Imfinzi (durvalumab), Bavencio (avelumab)], Pipeline Analysis, indication [non-small cell lung cancer (NSCLC), malignant melanoma (MM), kidney cancer (RCC), small cell lung cancer (SCLC), urogenital cancer, head and neck cancer (HNSCC), other cancers], and geography.

  • The PD-1/PD-L1 checkpoint inhibitors represent one of the most dynamic market segments and significantly outperformed the global oncology market over the past few years.
  • Based on the drug classes, the PD-1 inhibitors segment accounted for the largest share of the total PD-1/PD-L1 inhibitors market, whereas the PD-L1 inhibitors segment anticipated to expand at the fastest double-digit CAGR throughout the forecast period.
    • Among the PD-1 inhibitors segment, Keytruda established a dominant position, holding majority of the market share, as it is approved across 13 indications, and gained extensive data through clinical trials.
      • In many settings, Keytruda has also become the standard of care, including in the clinical trials.
      • Along with Keytruda, the other early entrant Opdivo expected to account for majority of the global checkpoint inhibitor market.
    • Among the PD-L1 inhibitors segment, Tecentriq and Imfinzi have gained sizeable share, whereas all other entrants account for a limited share of the global PD-1/PD-L1 inhibitors market between them.
  • In terms of the different tumor types, the non-small cell lung cancer (NSCLC) segment dominated the global PD-1 and PD-L1 inhibitors market, followed by malignant melanoma (MM), and kidney cancer (renal cell carcinoma), respectively.
    • Different indications are dominated by different checkpoint inhibitors, for example Keytruda is the leading agent in NSCLC, Opdivo dominates melanoma and renal cancer, and Tecentriq small cell lung cancer (SCLC).

Consequently, the success of checkpoint inhibitors is inextricably linked to biomarker innovation, their adoption and testing rates in routine clinical practice. The vast majority the clinical trials test combinations of PD-1/PD-L1 inhibitors with a broad range of modalities, spanning other immunotherapies, targeted therapies, chemotherapies and radiotherapies.

  • Despite the extraordinary impact PD-1/PD-L1 checkpoint inhibitors have had on transforming the treatment landscape and improving the prognosis and outcomes for many patients in different malignancies, unmet needs still exist.

The global market for PD-1 and PD-L1 inhibitorsresearch report is further segmented by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.

In addition, the global market for PD-1 and PD-L1 inhibitorsreport provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries. The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.

Major players operating in the global market for PD-1 and PD-L1 inhibitorsand profiled in this report include AstraZeneca plc (MedImmune, LLC), Bristol-Myers Squibb Company (Celgene Corp.), GlaxoSmithKline plc, Merck Co. & Inc., Ono Pharmaceutical Co., Ltd., Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Roche Holding AG (Chugai Pharmaceutical Co., Ltd.), and Sanofi S.A.

  • Product (Drug Class/Brand)
    • PD-1 Inhibitors
      • Keytruda (Pembrolizumab)
      • Opdivo (Nivolumab)
      • Libtayo (Cemiplimab)
      • Jemperli (Dostarlimab)
    • PD-L1 Inhibitors
      • Tecentriq (Atezolizumab)
      • Imfinzi (Durvalumab)
      • Bavencio (Avelumab)
  • Pipeline Analysis
  • Indication
    • Non-Small Cell Lung Cancer (NSCLC)
    • Malignant Melanoma (MM)
    • Kidney Cancer (RCC)
    • Small Cell Lung Cancer (SCLC)
    • Urogenital Cancer (Bladder, Prostate)
    • Head and Neck Cancer (HNSCC)
    • Other Cancers
  • Geography
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World
  • Company Profiles
    • AstraZeneca plc (MedImmune, LLC)
    • Bristol-Myers Squibb Company (Celgene Corp.)
    • GlaxoSmithKline plc
    • Merck Co. & Inc.
    • Ono Pharmaceutical Co., Ltd.
    • Pfizer, Inc.
    • Regeneron Pharmaceuticals, Inc.
    • Roche Holding AG (Chugai Pharmaceutical Co., Ltd.)
    • Sanofi S.A.

To request Table of Contents and Sample Pages of this report:
https://www.ihealthcareanalyst.com/report/pd-1-and-pd-l1-inhibitors-market/

Related publications:



    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]

    Subject*

    Message*

    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: sales@ihealthcareanalyst.com